Companies ›Healthcare ›6892.TWO

6892.TWO — TPEx Biotechnology & Medical Research

6892.Two

$25,00

Open in Charts → Attach watcher ⌖

— —

TWD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

2,3B TWD

P/E

—

EV / Rev

—

Div yield

0,00 %

Op margin

—

ROE

—

Net margin

—

Debt / equity

0,76

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

6892.TWO is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic products and services.

Business. 6892.TWO is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic products and services.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 6892.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 6892.TWO. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

6892.TWO is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic products and services.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

AI synthesis

GENERATED

6892.TWO has a market capitalization of 2,592,940,000 TWD and a debt-to-equity ratio of 0.76, indicating a moderate level of leverage. The company's enterprise value to revenue ratio is 62.36, suggesting a high valuation relative to its revenue. The company's operating cash flow is negative at -212,310,000 TWD, and its capital expenditure is -32,107,000 TWD, indicating ongoing investment in its operations.

In terms of profitability, 6892.TWO's financial performance is not disclosed in the provided data, making it difficult to assess its profitability relative to industry standards. However, the company's high enterprise value to revenue ratio suggests that it may be valued based on future growth potential rather than current earnings.

The company's revenue concentration is not specified in the provided data, so it is unclear whether it is heavily reliant on a few segments or geographic regions. This lack of information limits the ability to assess the company's exposure to specific markets or products.

The growth trajectory of 6892.TWO is not explicitly stated in the provided data. However, the company's negative operating cash flow and high enterprise value to revenue ratio suggest that it may be in a growth phase, potentially investing heavily in research and development or market expansion.

The company faces a medium liquidity risk, as indicated by its negative net cash position after subtracting total debt. The dilution risk is assessed as low, suggesting that the company is not expected to issue a significant number of new shares in the near term.

Recent events related to 6892.TWO are not detailed in the provided data, so it is unclear whether there have been any significant developments in the company's operations or financial status.

Key takeaways

6892.TWO has a high enterprise value to revenue ratio of 62.36, indicating a premium valuation relative to its revenue.
The company's debt-to-equity ratio is 0.76, suggesting a moderate level of leverage.
6892.TWO has a negative operating cash flow of -212,310,000 TWD, indicating ongoing investment in its operations.
The company's liquidity risk is assessed as medium, with a negative net cash position after subtracting total debt.
The dilution risk is assessed as low, suggesting that the company is not expected to issue a significant number of new shares in the near term.
"margin_outlook_rationale": "The company's margin outlook is uncertain due to the lack of detailed profitability data in the provided financial snapshot.",

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

$25,00

Market cap

$2.59B

Enterprise valueⓘ

$3.14B

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

-$551.4M

Current ratioⓘ

—

Debt / equityⓘ

0.8

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

-63.7%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Capex / Rev-63,7 %Bottom quartile

D/E0,76Bottom quartile

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue

Source documents

6892.TWO Market data — financials · 2026-05-27

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

6892.TWOCanonical

TPEx · TWD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread